Pharmafile Logo
Pharmafocus logo
Advanced Search

Sativex

Showing 9 posts of 9 posts found.

gwpharma

GW Pharma takes back control of UK Sativex sales from Bayer

March 2, 2020
Sales and Marketing Bayer, GW Pharma, Sativex, UK

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …

News
https__cdn

NHS to utilise first-ever cannabis-based therapies following NICE recommendation of two GW Pharma drugs

November 11, 2019
Sales and Marketing Epidyolex, GW Pharma, NHS, Sativex, pharma

The NHS is authorised to use its first two cannabis-based medicines for routine use after NICE saw fit to recommend …

News
Sativex

Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015
Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …

News
Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

News
Charity image

Charities must be clear about pharma funding

October 1, 2014
Medical Communications, Sales and Marketing ABPI, NICE, Sativex, charity, funding, mind, pharma

There is growing need for transparency around patient groups and health charities as they are widely perceived to be independent …

News
GW laboratory

Bayer launches world’s first cannabis-derived prescription drug

June 21, 2010
Sales and Marketing Bayer, GW Pharmaceuticals, Sativex

Bayer Healthcare has launched the world’s first cannabis-derived prescription drug in the UK. Sativex treats the spasticity symptoms of multiple …

News

Cannabis-derived MS drug filed for European approval

May 20, 2009
Research and Development, Sales and Marketing GW, Sativex

Sativex, the cannabis-derived product developed by GW Pharmaceuticals, could be finally set for European approval after five years of delay. …

News

Cannabis-derived MS treatment filed in Europe

September 5, 2006
Sales and Marketing GW Pharmaceuticals, Sativex

Sativex, the cannabis-derived product developed by GW Pharmaceuticals could be finally set for approval after a delay of around two …

News

Patient demand brings Sativex to UK ahead of approval

November 17, 2005
Sales and Marketing GW Pharmaceuticals, Sativex

The unlicensed cannabis-based medicine Sativex will be available in the UK to treat neuropathic pain on a named patient basis …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024